Vizsgálati helyszín
Oncology Hematology Care, Inc
Cincinnati, Ohio 45242, Egyesült ÁllamokMég nincs intézményhez kötve
- 19futó vizsgálat
- 8lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 27 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis15 vizsgálat
- 2. fázis6 vizsgálat
- 1. fázis2 vizsgálat
- 4. fázis2 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz10 vizsgálat
- Toboroz9 vizsgálat
- Lezárult8 vizsgálat
- Fő szponzor
- Eli Lilly and Company4 vizsgálat
- Novartis Pharmaceuticals4 vizsgálat
- Amgen3 vizsgálat
- Loxo Oncology, Inc.3 vizsgálat
- Gilead Sciences2 vizsgálat
- és még 9
Futó vizsgálatok
Toboroz
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
NCT07365995· 3. fázis· BioNTech SE· Forrás
Toboroz
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT07218341· 4. fázis· Eli Lilly and Company· Forrás
Contact: Kruti Patel (principal investigator)
Toboroz
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07023627· 2. fázis· Incyte Corporation· Forrás
Toboroz
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804· 3. fázis· Eli Lilly and Company· Forrás
Contact: Ajit Gubbi (principal investigator)
Fut, nem toboroz
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07005128· 3. fázis· Amgen· Forrás
Toboroz
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
NCT05868629· Novartis Pharmaceuticals· Forrás
Contact: Douglas Hart
Toboroz
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
NCT05722418· 1. fázis· Caribou Biosciences, Inc.· Forrás
Contact: Doug Hart
Toboroz
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654· 3. fázis· Gilead Sciences· Forrás
Fut, nem toboroz
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
NCT05456191· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
NCT05502237· 3. fázis· Gilead Sciences· Forrás
Toboroz
Asciminib Roll-over Study
NCT04877522· 4. fázis· Novartis Pharmaceuticals· Forrás
Contact: David Waterhouse (principal investigator)
Fut, nem toboroz
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
NCT05060016· 2. fázis· Amgen· Forrás
Fut, nem toboroz
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04965493· 3. fázis· Loxo Oncology, Inc.· Forrás
Fut, nem toboroz
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
NCT04662255· 3. fázis· Loxo Oncology, Inc.· Forrás
Fut, nem toboroz
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT04666038· 3. fázis· Loxo Oncology, Inc.· Forrás
Fut, nem toboroz
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
NCT04589845· 2. fázis· Hoffmann-La Roche· Forrás
Toboroz
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
NCT03435796· 2/3. fázis· Celgene· Forrás
Contact: James Essell, Site 01037
Fut, nem toboroz
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
NCT03522246· 3. fázis· pharmaand GmbH· Forrás
Fut, nem toboroz
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
NCT02152631· 3. fázis· Eli Lilly and Company· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek